Commentary|Videos|August 9, 2024

Identifying the Most Useful Features in Solutions from a Patient POV

In part 3 of this video interview, Vincent Keunen, founder & CEO of Andaman7 shares his own experience as a patient when it comes to using digital applications.

ACT: As a patient yourself, what specific features or functions do you look for in technology?

Keunen: I went through some difficult times with my cancer, with my son's cancer, and I realized that those times that it was very hard to have everything you needed. It's basically having access to the right information when you need it, so that's why I think a mobile phone is probably the only solution, because a computer won't work, even a tablet won't work. It's just too bulky, and you don't take your tablet with you all the time. That's why I'm a big, big advocate in having everything on the smartphone. I personally am also very concerned about privacy and data security, so I don't want my data to be in the cloud, and that's a big, big ask, I would say, because it's challenging to put everything on the phone and have the correct backups in case you lose your phone and so on, but I think it can be done. It has been done. We have proven that. For me, having everything on the smartphone, no data in the cloud, and very easy to use software is a first step. Then, if I decide to contribute to research, for example, it must be extremely easy and transparent, right? I want to know exactly what I'm doing and what is requested from me. I don't want anything to be under the table—it happens, still much too often, not only in the medical sector, but globally. You're being offered a tool, and then you become the product, as some say—I don't want that at all. It must be very obvious, and it must be a fair exchange of value. If I'm being given a very useful tool, and in return, they asked me to share some of my data, I can accept that, but it has to be a good exchange of value for both. So, easy features, all of my data very well protected by being only on the on the smartphone, and of course then being exchanged when I consent, and then having a trace of all of the data that has been exchanged is also probably very important.


Related to this article

© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
What It Actually Means to Embed the Patient Voice in Trial Design
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written—and what it looks like when patients and caregivers tell you a trial was designed with them in mind.